Mylan PE Ratio 2006-2019 | MYL

Current and historical p/e ratio for Mylan (MYL) from 2006 to 2019. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. Mylan PE ratio as of December 06, 2019 is 4.47.
Mylan PE Ratio Historical Data
Date Stock Price TTM Net EPS PE Ratio
2019-12-06 19.29 214.33
2019-09-30 19.78 $0.09 219.78
2019-06-30 19.04 $0.06 317.33
2019-03-31 28.34 $0.46 61.61
2018-12-31 27.40 $0.68 40.29
2018-09-30 36.60 $1.04 35.19
2018-06-30 36.14 $0.86 42.02
2018-03-31 41.17 $1.34 30.72
2017-12-31 42.31 $1.29 32.80
2017-09-30 31.37 $1.61 19.48
2017-06-30 38.82 $1.22 31.82
2017-03-31 38.99 $1.00 38.99
2016-12-31 38.15 $0.91 41.92
2016-09-30 38.12 $0.51 74.75
2016-06-30 43.24 $1.57 27.54
2016-03-31 46.35 $1.56 29.71
2015-12-31 54.07 $1.66 32.57
2015-09-30 40.27 $1.75 23.01
2015-06-30 67.86 $2.18 31.13
2015-03-31 59.35 $2.18 27.22
2014-12-31 56.37 $2.34 24.09
2014-09-30 45.49 $2.32 19.61
2014-06-30 51.56 $1.46 35.32
2014-03-31 48.83 $1.60 30.52
2013-12-31 43.40 $1.58 27.47
2013-09-30 38.17 $1.52 25.11
2013-06-30 31.03 $1.63 19.04
2013-03-31 28.96 $1.50 19.30
2012-12-31 27.45 $1.53 17.94
2012-09-30 24.37 $1.44 16.92
2012-06-30 21.37 $1.29 16.57
2012-03-31 23.45 $1.29 18.18
2011-12-31 21.46 $1.22 17.59
2011-09-30 16.99 $0.93 18.27
2011-06-30 24.67 $0.90 27.41
2011-03-31 22.66 $0.73 31.04
2010-12-31 21.13 $0.70 30.19
2010-09-30 18.81 $0.70 26.87
2010-06-30 17.04 $0.24 71.00
2010-03-31 22.71 $0.27 84.11
2009-12-31 18.43 $0.23 80.13
2009-09-30 16.01 $0.09 177.89
2009-06-30 13.05 $0.67 19.48
2009-03-31 13.41 $0.45 29.80
2008-12-31 9.89 $-1.17 0.00
2008-09-30 11.42 $-6.08 0.00
2008-06-30 12.07 $-5.93 0.00
2008-03-31 11.60 $-5.58 0.00
2007-12-31 14.06 $-4.43 0.00
2007-09-30 15.96 $1.24 12.87
2007-06-30 18.19 $1.00 18.19
2007-03-31 21.07 $1.03 20.46
2006-12-31 19.84 $1.34 14.81
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $9.956B $11.434B
Mylan NV is a pharmaceutical company. The company develops, licenses, manufactures, markets and distributes generic and specialty pharmaceuticals. It operates primarily in the United States, Canada, Europe, the Middle East, Africa, India, Australia, Japan and New Zealand. Mylan NV, formerly known as Mylan Inc., is based in Canonsburg, Pennsylvania.
Stock Name Country Market Cap PE Ratio
Allergan (AGN) Ireland $61.181B 11.15
Teva Pharmaceutical Industries (TEVA) Israel $10.834B 4.41
Bausch Health Cos (BHC) Canada $10.259B 6.77
Dr Reddy's Laboratories (RDY) India $6.698B 17.57
ASPEN PHARMACR (APNHY) South Africa $3.391B 0.00
Supernus Pharmaceuticals (SUPN) United States $1.198B 11.59
Amphastar Pharmaceuticals (AMPH) United States $0.888B 46.15
Homology Medicines (FIXX) United States $0.800B 0.00
Voyager Therapeutics (VYGR) United States $0.518B 0.00
Akorn (AKRX) United States $0.473B 0.00
Progenics Pharmaceuticals (PGNX) United States $0.442B 0.00
Assembly Biosciences (ASMB) United States $0.428B 0.00
Mallinckrodt Public Limited Company (MNK) United Kingdom $0.287B 0.39
Adamas Pharmaceuticals (ADMS) United States $0.180B 0.00
Sol-Gel Technologies (SLGL) Israel $0.158B 0.00
Zynerba Pharmaceuticals (ZYNE) United States $0.131B 0.00
CymaBay Therapeutics (CBAY) United States $0.120B 0.00
Teligent (TLGT) United States $0.033B 0.00